JP2014526456A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014526456A5 JP2014526456A5 JP2014529039A JP2014529039A JP2014526456A5 JP 2014526456 A5 JP2014526456 A5 JP 2014526456A5 JP 2014529039 A JP2014529039 A JP 2014529039A JP 2014529039 A JP2014529039 A JP 2014529039A JP 2014526456 A5 JP2014526456 A5 JP 2014526456A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- group
- cip2a
- subject
- activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101000766826 Homo sapiens Protein CIP2A Proteins 0.000 claims 10
- 102100028634 Protein CIP2A Human genes 0.000 claims 10
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 230000030279 gene silencing Effects 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 230000003463 hyperproliferative effect Effects 0.000 claims 5
- 230000002950 deficient Effects 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 239000007787 solid Substances 0.000 claims 4
- JAMULYFATHSZJM-UHFFFAOYSA-N 8-(4-dibenzothiophenyl)-2-(4-morpholinyl)-1-benzopyran-4-one Chemical compound O1C2=C(C=3C=4SC5=CC=CC=C5C=4C=CC=3)C=CC=C2C(=O)C=C1N1CCOCC1 JAMULYFATHSZJM-UHFFFAOYSA-N 0.000 claims 3
- CPRAGQJXBLMUEL-UHFFFAOYSA-N 9-(1-anilinoethyl)-7-methyl-2-(4-morpholinyl)-4-pyrido[1,2-a]pyrimidinone Chemical compound C=1C(C)=CN(C(C=C(N=2)N3CCOCC3)=O)C=2C=1C(C)NC1=CC=CC=C1 CPRAGQJXBLMUEL-UHFFFAOYSA-N 0.000 claims 3
- 102000053642 Catalytic RNA Human genes 0.000 claims 3
- 108090000994 Catalytic RNA Proteins 0.000 claims 3
- IVYPNXXAYMYVSP-UHFFFAOYSA-N Indole-3-carbinol Natural products C1=CC=C2C(CO)=CNC2=C1 IVYPNXXAYMYVSP-UHFFFAOYSA-N 0.000 claims 3
- 239000012661 PARP inhibitor Substances 0.000 claims 3
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 claims 3
- HWNUSGNZBAISFM-UHFFFAOYSA-N S3I-201 Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OCC(=O)NC1=CC=C(C(O)=O)C(O)=C1 HWNUSGNZBAISFM-UHFFFAOYSA-N 0.000 claims 3
- 108091027967 Small hairpin RNA Proteins 0.000 claims 3
- 108020004459 Small interfering RNA Proteins 0.000 claims 3
- 239000000074 antisense oligonucleotide Substances 0.000 claims 3
- 238000012230 antisense oligonucleotides Methods 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 3
- 229960004316 cisplatin Drugs 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 3
- 229960005277 gemcitabine Drugs 0.000 claims 3
- RUMVKBSXRDGBGO-UHFFFAOYSA-N indole-3-carbinol Chemical compound C1=CC=C[C]2C(CO)=CN=C21 RUMVKBSXRDGBGO-UHFFFAOYSA-N 0.000 claims 3
- 235000002279 indole-3-carbinol Nutrition 0.000 claims 3
- 108091070501 miRNA Proteins 0.000 claims 3
- 239000002679 microRNA Substances 0.000 claims 3
- 229950010895 midostaurin Drugs 0.000 claims 3
- BMGQWWVMWDBQGC-IIFHNQTCSA-N midostaurin Chemical compound CN([C@H]1[C@H]([C@]2(C)O[C@@H](N3C4=CC=CC=C4C4=C5C(=O)NCC5=C5C6=CC=CC=C6N2C5=C43)C1)OC)C(=O)C1=CC=CC=C1 BMGQWWVMWDBQGC-IIFHNQTCSA-N 0.000 claims 3
- 239000002243 precursor Substances 0.000 claims 3
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 3
- 108091092562 ribozyme Proteins 0.000 claims 3
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 3
- 229960002930 sirolimus Drugs 0.000 claims 3
- 239000004055 small Interfering RNA Substances 0.000 claims 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 108091034117 Oligonucleotide Proteins 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 230000006870 function Effects 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 2
- 201000005787 hematologic cancer Diseases 0.000 claims 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 2
- 150000007523 nucleic acids Chemical group 0.000 claims 2
- 238000011275 oncology therapy Methods 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 108020000948 Antisense Oligonucleotides Proteins 0.000 claims 1
- 206010003571 Astrocytoma Diseases 0.000 claims 1
- 208000004736 B-Cell Leukemia Diseases 0.000 claims 1
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- 101150012946 CIP2A gene Proteins 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 101100220707 Homo sapiens CIP2A gene Proteins 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010070834 Sensitisation Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 208000030224 brain astrocytoma Diseases 0.000 claims 1
- 208000024055 brain glioblastoma Diseases 0.000 claims 1
- 201000011609 brain glioblastoma multiforme Diseases 0.000 claims 1
- 201000007983 brain glioma Diseases 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 230000002518 glial effect Effects 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 230000002489 hematologic effect Effects 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 230000004952 protein activity Effects 0.000 claims 1
- 230000008313 sensitization Effects 0.000 claims 1
- 230000001235 sensitizing effect Effects 0.000 claims 1
- 230000001743 silencing effect Effects 0.000 claims 1
- 238000009097 single-agent therapy Methods 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161531337P | 2011-09-06 | 2011-09-06 | |
| FI20115876 | 2011-09-06 | ||
| US61/531,337 | 2011-09-06 | ||
| FI20115876A FI20115876A0 (fi) | 2011-09-06 | 2011-09-06 | Yhdistelmähoito |
| PCT/FI2012/050862 WO2013034806A1 (en) | 2011-09-06 | 2012-09-06 | Pharmaceutical combination comprising a cip2a silencing agent for use in the treatment of a hyperproliferative disorder, preferably one with impaired p53 function |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014526456A JP2014526456A (ja) | 2014-10-06 |
| JP2014526456A5 true JP2014526456A5 (enExample) | 2015-12-17 |
| JP6060164B2 JP6060164B2 (ja) | 2017-01-11 |
Family
ID=44718785
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014529039A Expired - Fee Related JP6060164B2 (ja) | 2011-09-06 | 2012-09-06 | 過剰増殖性疾患、好ましくはｐ５３機能欠損の治療に用いるためのＣＩＰ２Ａサイレンシング剤を含む併用薬剤 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US9457042B2 (enExample) |
| EP (2) | EP3311815A1 (enExample) |
| JP (1) | JP6060164B2 (enExample) |
| CN (1) | CN103917228B (enExample) |
| CA (1) | CA2847810C (enExample) |
| DK (1) | DK2753316T3 (enExample) |
| ES (1) | ES2650742T3 (enExample) |
| FI (1) | FI20115876A0 (enExample) |
| WO (1) | WO2013034806A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS62447B1 (sr) | 2012-11-16 | 2021-11-30 | Calithera Biosciences Inc | Heterociklični inhibitori glutaminaze |
| KR20170012562A (ko) * | 2014-06-13 | 2017-02-02 | 칼리테라 바이오사이언시즈 인코포레이티드 | 글루타미나제 억제제를 사용하는 병용 요법 |
| US10316030B2 (en) | 2014-08-07 | 2019-06-11 | Calithera Biosciences, Inc. | Crystal forms of glutaminase inhibitors |
| EP3359150A4 (en) | 2015-10-05 | 2019-11-06 | Calithera Biosciences, Inc. | COMBINATION THERAPY WITH GLUTAMINASE INHIBITORS AND IMMUNO-ONCOLOGICAL AGENTS |
| CN105467119A (zh) * | 2015-11-28 | 2016-04-06 | 上海交通大学医学院附属第三人民医院 | 一种预测大肠癌细胞对p38MAPK激酶抑制剂敏感性的方法 |
| CA3047027A1 (en) * | 2016-12-14 | 2018-06-21 | Shanghaitech University | Compositions and methods for treating cancer by inhibiting piwil4 |
| EP3600341A4 (en) * | 2017-03-19 | 2022-07-06 | Suzhou Sirnaomics Biopharmaceuticals Co., Ltd. | GEMCITA BIN DERIVATIVES FOR CANCER THERAPY |
| WO2018183868A1 (en) * | 2017-03-31 | 2018-10-04 | Bioventures, Llc | Inhibitors of dna pk and uses thereof |
| WO2018218633A1 (en) | 2017-06-02 | 2018-12-06 | Beijing Percans Oncology Co. Ltd. | Combination therapies for treating cancers |
| WO2019195959A1 (en) | 2018-04-08 | 2019-10-17 | Cothera Biosciences, Inc. | Combination therapy for cancers with braf mutation |
| SG11202101397TA (en) * | 2018-08-13 | 2021-03-30 | Beijing Percans Oncology Co Ltd | Biomarkers for cancer therapy |
| JP2023525855A (ja) * | 2020-05-15 | 2023-06-19 | 上海科技大学 | コロナウイルスによる疾患の治療及び／又は予防のための化合物及びその使用 |
| KR102436309B1 (ko) * | 2020-05-26 | 2022-08-25 | 연세대학교 산학협력단 | 암의 예방 또는 치료용 약학적 조성물 |
| CN111549033B (zh) * | 2020-06-11 | 2021-02-12 | 南京市江宁医院 | 慢病毒感染人表皮角质细胞株及其构建方法和应用 |
| CN113663075B (zh) * | 2021-09-14 | 2023-03-21 | 清华大学深圳国际研究生院 | Pcsk9抑制剂在制备治疗或辅助治疗肿瘤的药物中的应用 |
| CN116870167B (zh) * | 2023-08-24 | 2024-11-08 | 四川大学 | 一种用于治疗实体肿瘤的联合用药物和药物组合物 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5843684A (en) * | 1990-06-27 | 1998-12-01 | The Trustees Of Princeton University | Method for detecting pre-cancerous or cancerous cells using P90 antibodies or probes |
| EP0654092B1 (en) * | 1992-06-26 | 2003-09-10 | The Trustees Of Princeton University | Method for detecting pre-cancerous or cancerous cells using p90 and p53 antibodies or probes |
| WO2002081628A2 (en) | 2001-04-05 | 2002-10-17 | Ribozyme Pharmaceuticals, Incorporated | Modulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies |
| US20030190635A1 (en) | 2002-02-20 | 2003-10-09 | Mcswiggen James A. | RNA interference mediated treatment of Alzheimer's disease using short interfering RNA |
| US20030175950A1 (en) | 2001-05-29 | 2003-09-18 | Mcswiggen James A. | RNA interference mediated inhibition of HIV gene expression using short interfering RNA |
| US20040019001A1 (en) | 2002-02-20 | 2004-01-29 | Mcswiggen James A. | RNA interference mediated inhibition of protein typrosine phosphatase-1B (PTP-1B) gene expression using short interfering RNA |
| AU2003279010A1 (en) | 2002-09-28 | 2004-04-19 | Massachusetts Institute Of Technology | Compositions and methods for delivery of short interfering rna and short hairpin rna |
| EP2213738B1 (en) | 2002-11-14 | 2012-10-10 | Dharmacon, Inc. | siRNA molecules targeting Bcl-2 |
| US20050043266A1 (en) | 2003-07-25 | 2005-02-24 | Sumedha Jayasena | Short interfering RNA as an antiviral agent for hepatitis C |
| US20060115453A1 (en) * | 2004-11-12 | 2006-06-01 | Yaffe Michael B | Methods and compositions for treating cellular proliferative diseases |
| US20080021198A1 (en) | 2005-10-12 | 2008-01-24 | Yigong Shi | Modulators of protein phosphatase 2A and PP2A methyl esterase |
| US20090029966A1 (en) * | 2006-01-17 | 2009-01-29 | Abbott Laboratories | Combination therapy with parp inhibitors |
| FI20060246A0 (fi) | 2006-03-16 | 2006-03-16 | Jukka Westermarck | Uusi kasvua stimuloiva proteiini ja sen käyttö |
| US20100279327A1 (en) * | 2006-06-12 | 2010-11-04 | Bipar Sciences, Inc. | Method of treating diseases with parp inhibitors |
| GB0612542D0 (en) | 2006-06-23 | 2006-08-02 | Novartis Ag | Combinations comprising staurosporines |
| WO2008094321A2 (en) | 2006-10-04 | 2008-08-07 | Universtiy Of South Florida | Akt sensitization of cancer cells |
| NZ586125A (en) * | 2007-11-12 | 2012-12-21 | Bipar Sciences Inc | Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents |
| US20090274682A1 (en) | 2008-02-05 | 2009-11-05 | The Trustees Of Princeton University | Demethylation and inactivation of protein phosphatase 2a |
| CN101352444A (zh) | 2008-09-11 | 2009-01-28 | 中国科学院广州生物医药与健康研究院 | 雷公藤红素在制药中的新应用 |
-
2011
- 2011-09-06 FI FI20115876A patent/FI20115876A0/fi not_active Application Discontinuation
-
2012
- 2012-09-06 CA CA2847810A patent/CA2847810C/en not_active Expired - Fee Related
- 2012-09-06 JP JP2014529039A patent/JP6060164B2/ja not_active Expired - Fee Related
- 2012-09-06 WO PCT/FI2012/050862 patent/WO2013034806A1/en not_active Ceased
- 2012-09-06 ES ES12762321.3T patent/ES2650742T3/es active Active
- 2012-09-06 EP EP17199400.7A patent/EP3311815A1/en not_active Withdrawn
- 2012-09-06 DK DK12762321.3T patent/DK2753316T3/en active
- 2012-09-06 CN CN201280054472.4A patent/CN103917228B/zh not_active Expired - Fee Related
- 2012-09-06 US US14/343,015 patent/US9457042B2/en not_active Expired - Fee Related
- 2012-09-06 EP EP12762321.3A patent/EP2753316B1/en not_active Not-in-force
-
2016
- 2016-09-01 US US15/254,312 patent/US9968630B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014526456A5 (enExample) | ||
| Zhang et al. | Exosome-mediated transfer of lncRNA RP11-838N2. 4 promotes erlotinib resistance in non-small cell lung cancer | |
| Wu et al. | Multi-drug resistance in cancer chemotherapeutics: mechanisms and lab approaches | |
| Cheng et al. | AS1411-induced growth inhibition of glioma cells by up-regulation of p53 and down-regulation of Bcl-2 and Akt1 via nucleolin | |
| JP6060164B2 (ja) | 過剰増殖性疾患、好ましくはｐ５３機能欠損の治療に用いるためのＣＩＰ２Ａサイレンシング剤を含む併用薬剤 | |
| Zheng et al. | Super-enhancer-controlled positive feedback loop BRD4/ERα–RET–ERα promotes ERα-positive breast cancer | |
| JP2018508469A5 (enExample) | ||
| Ren et al. | Pimozide suppresses colorectal cancer via inhibition of Wnt/β-catenin signaling pathway | |
| US20140348819A1 (en) | Methods of Treating Cancer | |
| JP2013511560A5 (enExample) | ||
| WO2019201195A1 (zh) | 预防或治疗肿瘤疗法副作用的方法 | |
| JP2014523398A5 (enExample) | ||
| JP2014523426A5 (enExample) | ||
| JPWO2019189772A1 (ja) | 長鎖ノンコーディングｒｎａを標的とするがん治療剤およびがん診断方法 | |
| CN115803629A (zh) | 使用HIF-2α抑制剂和乐伐替尼的组合治疗癌症或VON-HIPPEL LINDAU病的方法 | |
| CN105497896A (zh) | 一种肿瘤耐药的靶点及其应用 | |
| Turgambayeva et al. | Role of TRP channels in carcinogenesis and metastasis: Pathophysiology and regulation by non-coding RNAs | |
| WO2021073535A1 (zh) | 预防或治疗与vegfr和/或vegf被抑制相关疾病的方法 | |
| CN106714795A (zh) | 用于治疗尤因家族肿瘤的组合物及方法 | |
| WO2024118897A1 (en) | Cancer treatments using a prmt5 inhibitor and a mat2a inhibitor | |
| KR20180103816A (ko) | 췌장암을 치료하기 위한 조성물과 방법 | |
| Cao et al. | Targeting NUCKS1 with a fragment of tRNAAsn (GUU) of Chinese yew for the treatment of colorectal cancer | |
| Ross et al. | Tmic-14. Hypoxia Inducible Olig2 Mediates Glioma Stem Cell Migration | |
| Cao et al. | Targeting NUCKS1 with a fragment of tRNA Asn (GUU) of Chinese yew for the treatment of colorectal cancer. | |
| Miyadera et al. | 142 TAS-2913 is a Mutant Selective EGFR Inhibitor for NSCLC: Characterization Against EGFR T790M in Cell and Xenograft Models |